Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
MSB
MSB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MSB News
MESOBLAST GETS FDA IND APPROVAL TO INITIATE REGISTRATIONAL TRIAL FOR RYONCIL
Apr 08 2026
moomoo
MESOBLAST LTD - FDA Approves RYONCIL IND for DMD Registration Trial
Apr 08 2026
moomoo
MESOBLAST LTD - RYONCIL QUARTERLY NET REVENUE RISES TO US$30.3M
Apr 07 2026
moomoo
Market Dynamics and Corporate Changes
Mar 13 2026
CNBC
Mesabi Trust (MSB) Declares $0.26 Quarterly Dividend Payable February 20
Jan 19 2026
seekingalpha
Mesoblast Receives FDA Feedback for BLA Filing of rexlemestrocel-L
Jan 19 2026
NASDAQ.COM
Mesoblast Reports 60% Revenue Growth to $35.1 Million in Q4
Jan 09 2026
Globenewswire
Mesoblast Appoints New Chair to Drive Commercialization Efforts
Jan 01 2026
Globenewswire
Mesoblast Presents Superior Efficacy of Remestemcel-L Over Ruxolitinib for SR-aGvHD
Dec 12 2025
Newsfilter
Mesoblast Participates in Piper Sandler Healthcare Conference, CEO to Speak
Dec 03 2025
Globenewswire
Mesoblast Projects Over $30 Million in Quarterly Revenue from Ryoncil
Nov 25 2025
Newsfilter
Mesabi Trust Announces News Release
Oct 10 2025
Newsfilter
Mesabi Trust Announces News Release
Sep 26 2025
Newsfilter
Mesabi Trust declares $0.12 dividend
Jul 14 2025
SeekingAlpha
Mesabi Trust Press Release
May 02 2025
Newsfilter
Mesabi Trust declares $0.56 dividend
Apr 16 2025
SeekingAlpha
Show More News